Amsterdam
-
Amsterdam Molecular Therapeutics Reports Promising Data
Amsterdam Molecular Therapeutics (AMT) reports positive preclinical data from a study using an AAV gene therapy product to lower cholesterol. The data show that a single dose of the gene therapy carrying a short hairpin RNA to silence Apolipoprotein…
Amsterdam | 04 June 2010
-
EMA Starts Formal Review of LPLD Drug
Amsterdam Molecular Therapeutics has reached another milestone in the official marketing authorization process for its lead product Glybera, for Lipoprotein Lipase Deficiency (LPLD). The submission of the Marketing Authorisation Application (MAA)…
Amsterdam | 28 January 2010
-
AMT Starts Development of LPLD Diagnostic Tool
Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma have entered into a development and commercialization agreement for LPLchip, a diagnostic tool to rapidly diagnose patients with complete and partial Lipoprotein Lipase Deficiency (LPLD).…
Amsterdam | 13 November 2009
-
AMT Receives Orphan Drug Designation for DMD Treatment
Amsterdam Molecular Therapeutics (AMT) has announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to the former’s gene therapy product AMT-080 for the treatment of Duchenne Muscular Dystrophy (DMD). Orphan Drug …
Amsterdam | 22 October 2009
